Navigation Links
Alexza to Webcast Investor and Analyst Day Presentations
Date:4/22/2008

MOUNTAIN VIEW, Calif., April 22 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will host a live audio webcast of presentations given at the Company's Investor and Analyst Day on Tuesday, April 29th, 2008. Leading medical experts will discuss the Phase 1 and Phase 2 results of the Company's clinical trials, provide an overview of the Phase 3 trial design for AZ-004 (Staccato(R) loxapine), and discuss the role that AZ-004 may play in treating acute agitation in schizophrenic or bipolar disorder patients. Alexza senior management will also provide an overview of Alexza's other clinical stage product candidates.

What: Presentations (Audio & Slides)

Who: Dr. Michael Allen - University of Colorado Health Sciences

Center

Associate Professor of Psychiatry

Director, Emergency and Consultation Psychiatry

Co-Director, Mood Disorders Program

Past President and Trustee, American Association for

Emergency Psychiatry

Dr. Carol Tamminga -- University of Texas Southwestern

Medical Center

Professor of Psychiatry

Vice Chair for Clinical Research

Chief of Translational Neuroscience Research in

Schizophrenia

Communities Foundation of Texas Chair in Brain Science

When: Tuesday, April 29th, 2008 at 12:15-3:00 p.m. EDT

Where: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-

eventDetails&c=196151&eventID=1831771

or

http://www.alexza.com/investor_section/news_events.php

How: Live over the Internet -- Simply log on to the Web at the

address above and register for the event (approximately 10

minutes beforehand)

If you are unable to participate during the live webcast, the call will be archived on Alexza's website at http://www.alexza.com.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated webcast and presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission, including the risks under the headings. Forward-looking statements contained in the webcast and presentations are made as of their date of presentation, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
2. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
3. Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
4. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
5. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
6. Johnson & Johnson to Webcast Annual Meeting of Shareholders
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
9. ResMed to Webcast Third Quarter 2008 Earnings Conference Call
10. CTG Announces 2008 First Quarter Conference Call and Webcast Information
11. MSA Schedules First Quarter Earnings Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... work, the Self-Funding Success website has recently developed and published an informational resource ... ” was created based on common inquiries the site’s team of third party ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... ... , ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in ... hair loss. Although hair transplant procedures can be seen as more of a man’s ... be two reasons a woman may see her hair thinning. , “We are used ...
(Date:3/28/2017)... ... 28, 2017 , ... Nurse practitioners and physician assistants are ... in the healthcare workforce, according to a survey recently released by PracticeMatch ... candidate leads to healthcare employers of physicians and advanced practice clinicians. , Only ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  Medeon Biodesign, Inc., a ... to announce that the Company led and successfully ... Inc., a San Jose, CA ... orthopedic extremity applications.  The orthopedic ... due to procedure volume growth, lifestyle influences and ...
(Date:3/27/2017)... The National University of Singapore (NUS) ... company, signed a Memorandum of Understanding (MOU) recently ... the region. Under this MOU, ... Technology (BIGHEART) at NUS and Holmusk will establish ... healthcare IT and medical device development. These include ...
(Date:3/27/2017)... -- Summary This report provides all ... its partnering interests and activities since 2010. Description The ... insight into the partnering activity of one of the world,s ... are prepared upon purchase to ensure inclusion of the most ... report will be delivered in PDF format within 1 working ...
Breaking Medicine Technology: